{
  "@context": "aku-v2",
  "@type": "definition",
  "@id": "vascular:thrombophilia:antiphospholipid:definition",
  "metadata": {
    "version": "1.1.0",
    "created": "2026-01-05T18:05:00.000Z",
    "last_updated": "2026-01-05T18:35:00.000Z",
    "contributors": ["copilot", "fact-checking-agent"],
    "status": "validated",
    "confidence": 0.95,
    "review_notes": "Updated INR targets to reflect 2019 EULAR/ACR guidelines and ongoing clinical debate"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/thrombophilia",
    "type": "definition",
    "difficulty": "advanced",
    "importance": "critical",
    "board_yield": "HIGH"
  },
  "content": {
    "term": "Antiphospholipid Syndrome",
    "synonyms": ["APS", "APLS", "Hughes Syndrome", "Lupus Anticoagulant Syndrome"],
    "definition": "An acquired autoimmune thrombophilia characterized by persistent antiphospholipid antibodies and clinical manifestations of arterial and/or venous thrombosis and/or pregnancy morbidity. APS is unique among thrombophilias in causing both arterial and venous thrombosis.",
    "classification": {
      "primary_aps": "APS without underlying autoimmune disease",
      "secondary_aps": "APS with underlying disease (SLE most common)",
      "catastrophic_aps": "Rare, life-threatening multi-organ failure"
    },
    "pathophysiology": {
      "antibodies": [
        "Lupus anticoagulant (LA)",
        "Anticardiolipin antibodies (aCL)",
        "Anti-β2 glycoprotein I antibodies"
      ],
      "mechanisms": [
        "Endothelial cell activation",
        "Platelet activation",
        "Complement activation",
        "Interference with natural anticoagulants",
        "Impaired fibrinolysis"
      ]
    },
    "clinical_manifestations": {
      "venous_thrombosis": [
        "DVT (most common manifestation)",
        "Pulmonary embolism",
        "Cerebral venous thrombosis",
        "Hepatic/portal vein thrombosis",
        "Unusual sites"
      ],
      "arterial_thrombosis": [
        "Stroke/TIA (common)",
        "MI",
        "Peripheral arterial occlusion",
        "Renal artery thrombosis"
      ],
      "pregnancy_morbidity": [
        "Recurrent early pregnancy loss",
        "Fetal death after 10 weeks",
        "Preeclampsia",
        "Placental insufficiency"
      ],
      "other": [
        "Livedo reticularis",
        "Thrombocytopenia",
        "Libman-Sacks endocarditis",
        "Sneddon syndrome (livedo + stroke)"
      ]
    },
    "diagnosis": {
      "sydney_criteria": {
        "clinical_criteria": [
          "Vascular thrombosis (arterial/venous)",
          "Pregnancy morbidity"
        ],
        "laboratory_criteria": [
          "Lupus anticoagulant positive (2 occasions 12 weeks apart)",
          "Anticardiolipin IgG/IgM (medium-high titer)",
          "Anti-β2 glycoprotein I IgG/IgM"
        ],
        "requires": "At least 1 clinical + 1 laboratory criterion"
      },
      "triple_positive": "All 3 antibodies present = highest thrombosis risk"
    },
    "management": {
      "acute_thrombosis": "Heparin (UFH or LMWH) → warfarin",
      "long_term": {
        "warfarin_preferred": "INR target 2-3 for most patients including venous events",
        "arterial_events": "INR 2-3 recommended (2019 EULAR/ACR); some experts use 3-4 for recurrent arterial events - individualize",
        "doacs": "NOT recommended (inferior efficacy in APS - TRAPS trial)",
        "duration": "Lifelong anticoagulation for confirmed APS"
      },
      "pregnancy": [
        "LMWH + low-dose aspirin",
        "Close monitoring",
        "Avoid warfarin (teratogenic)"
      ],
      "catastrophic_aps": [
        "Anticoagulation + steroids",
        "Plasma exchange",
        "IVIG",
        "Rituximab for refractory cases"
      ]
    }
  },
  "codes": {
    "snomed_ct": "68088005",
    "icd_10": "D68.61"
  },
  "relationships": {
    "broader": ["vascular:thrombophilia:acquired"],
    "related": ["vascular:dvt", "vascular:stroke:young", "vascular:pregnancy-loss"],
    "narrower": []
  },
  "pedagogical": {
    "learning_objectives": [
      "Know the diagnostic criteria for APS",
      "Understand that APS causes both arterial AND venous thrombosis",
      "Know why warfarin is preferred over DOACs"
    ],
    "clinical_pearls": [
      "APS is ONLY thrombophilia that causes BOTH arterial and venous thrombosis",
      "Warfarin is SUPERIOR to DOACs in APS - DOACs have higher failure rate (TRAPS trial)",
      "Triple-positive (all 3 antibodies) = highest thrombosis risk",
      "Must confirm antibodies on 2 occasions 12 weeks apart",
      "Paradox: lupus anticoagulant causes thrombosis (not bleeding)",
      "Catastrophic APS: multi-organ failure - high mortality",
      "INR 2-3 is standard; higher targets for arterial events are debated"
    ]
  }
}
